Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $19.00 Price Target at TD Cowen

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target hoisted by TD Cowen from $18.00 to $19.00 in a report released on Wednesday,Benzinga reports. TD Cowen currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities analysts have also issued reports on the stock. Morgan Stanley lifted their target price on shares of Ultragenyx Pharmaceutical from $20.00 to $22.00 and gave the company an “equal weight” rating in a report on Wednesday. Wall Street Zen raised shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. The Goldman Sachs Group lowered their price objective on shares of Ultragenyx Pharmaceutical from $19.00 to $17.00 and set a “neutral” rating on the stock in a research note on Wednesday. Canaccord Genuity Group increased their price target on shares of Ultragenyx Pharmaceutical from $37.00 to $39.00 and gave the stock a “buy” rating in a research report on Friday, September 18th. Finally, Wells Fargo & Company boosted their price objective on shares of Ultragenyx Pharmaceutical from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $30.47.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE opened at $17.16 on Wednesday. Ultragenyx Pharmaceutical has a 1-year low of $12.73 and a 1-year high of $39.89. The company has a market capitalization of $1.69 billion, a P/E ratio of -3.31 and a beta of 0.37. The firm’s 50 day simple moving average is $16.45 and its 200 day simple moving average is $22.78.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing the consensus estimate of ($1.10) by ($0.06). The firm had revenue of $173.00 million during the quarter, compared to analysts’ expectations of $182.49 million. During the same quarter in the prior year, the company posted ($1.81) EPS. The company’s revenue for the quarter was up 8.2% on a year-over-year basis. On average, equities analysts anticipate that Ultragenyx Pharmaceutical will post -4.30 earnings per share for the current year.

Insider Activity

In related news, CFO Howard Horn sold 7,066 shares of the business’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $15.27, for a total transaction of $107,897.82. Following the completion of the transaction, the chief financial officer directly owned 89,229 shares in the company, valued at approximately $1,362,526.83. The trade was a 7.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 8,510 shares of company stock worth $127,561. Insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Ultragenyx Pharmaceutical in the second quarter worth approximately $355,746,000. Bank of America Corp DE bought a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter valued at $38,347,000. Candriam S.C.A. raised its position in shares of Ultragenyx Pharmaceutical by 37.1% during the 1st quarter. Candriam S.C.A. now owns 1,096,182 shares of the biopharmaceutical company’s stock valued at $22,965,000 after purchasing an additional 296,798 shares during the period. Jefferies Financial Group Inc. bought a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter valued at $31,040,000. Finally, Eagle Health Investments LP purchased a new position in shares of Ultragenyx Pharmaceutical during the 1st quarter valued at $18,522,000. Institutional investors own 97.67% of the company’s stock.

Key Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Ultragenyx reaffirmed its 2026 revenue and 2027 profitability outlook. It also said expense reductions are expected to cut 2027 R&D spending by at least 50% versus 2025, and it has agreements to sell two priority review vouchers for a combined $413 million. The company also reported FDA approval of GENGLYCOS and FAYUVI in the third quarter. Company earnings release
• Neutral Sentiment: Analyst actions were mixed. TD Cowen raised its target to $19 and kept a Buy rating; Canaccord cut its target to $34 but retained Buy. Morgan Stanley raised its target to $22 with an Equal Weight rating, while Goldman Sachs and Wedbush lowered targets to $17 and $22, respectively, and kept neutral ratings. Analyst ratings
• Negative Sentiment: Third-quarter revenue was $173 million, up 8.2% year over year but below the $182.49 million consensus. The $1.16-per-share loss also missed estimates of $1.10. A Seeking Alpha analysis additionally flagged reliance on CRYSVITA, limited contributions from newer launches, and pipeline setbacks; it argued the profitability pivot depends heavily on deep R&D cuts. Seeking Alpha analysis

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs.

Ultragenyx’s commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders.